Uncategorized

News of the cuts comes 13 months after the company outlined plans to eliminate 3,000 positions.

At least six federal lawsuits seeking class-action status were filed since the cyberattack, alleging the technology firm didn’t have reasonable cybersecurity measures in place.

The FDA’s decision allows people who don’t take insulin, including those who don’t have diabetes, to use the devices without a prescription.

The administration seeks to significantly increase the number of drugs each year that would be subjected to price negotiations under provisions of the Inflation Reduction Act. 

Chemomab Therapeutics, Ltd. today announced financial and operating results for the full year and fourth quarter ended December 31, 2023, and provided a corporate update.

RDS, the medical device start-up, today announces the granting of the CE mark for MultiSense®, its patented, wearable solution for continuous Remote Patient Monitoring.

Citius Pharmaceuticals, Inc. today announced that the Company has received $2.4 million in non-dilutive capital.

Gabather AB reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather’s GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Senzime Senzime, an industry leader in precision-based patient monitoring solutions, announces its largest hospital win to date.

La Luna, nuestro vecino celestial más cercano, ha sido durante mucho tiempo un punto de interés para la exploración espacial y científica. Pero ¿qué pasaría si instaláramos un telescopio astronómico en su misteriosa cara oculta?   …